Prescription-compounded scalp serums offer higher therapeutic concentrations than OTC hair products, and topical delivery is generally preferred over injectable for follicle-targeted goals
The Regulatory Reality of 2026: What Actually Changed In late 2023, the FDA moved 19 peptides, including BPC-157, to what's known as "Category 2" status under its framework for bulk drug substances used in compounding, identifying them as substances that "may present significant safety risks." The concern, as stated in FDA guidance, centered on the limited large-scale human data and questions about immunogenicity
Kang D, Shi B, Erfe MC, Craft N, Li H
Thats life-changing efficacy
Rated 5 out of 5 Anonymous Rated 5 out of 5 Heather Moxley Rated 5 out of 5 Anonymous Rated 5 out of 5 Elorah Gray Rated 5 out of 5 Erika S